SCHEMBL30452828

SCHEMBL30452828

Nc1nc(NCCc2ccc(-c3nnn(Cc4cccnc4)n3)cc2)nc2nc(-c3ccco3)nn12

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 18/20 0.63
ADORA3 P0DMS8 2/20 0.63
ADORA2B P29275 2/20 0.63
ADORA1 P30542 2/20 0.63
ALDH1A1 P00352 1/20 0.63
CYP1A2 P05177 1/20 0.63
CYP3A4 P08684 1/20 0.63
CYP2D6 P10635 1/20 0.63
CYP2C9 P11712 1/20 0.63
MAPK1 P28482 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
TMEM97 Q5BJF2 1/20 0.63
HSD17B10 Q99714 1/20 0.63
HDAC1 Q13547 10/20 0.59
HDAC6 Q9UBN7 7/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23828915 1.00 ADORA2A (0.63) ADORA2AADORA3ADORA2BADORA1ALDH1A1
SCHEMBL23828885 0.91 ADORA2A (0.66) ADORA2AADORA3ADORA2BADORA1ALDH1A1
SCHEMBL23828910 0.91 ADORA2A (0.68) ADORA2AADORA3ADORA2BADORA1ALDH1A1
SCHEMBL23581271 0.87 ADORA2A (0.72) ADORA2AADORA3ADORA2BADORA1ALDH1A1
SCHEMBL29837353 0.87 ADORA2A (0.72) ADORA2AADORA3ADORA2BADORA1ALDH1A1
SCHEMBL23581229 0.86 ADORA2A (0.70) ADORA2AADORA3ADORA2BADORA1ALDH1A1
SCHEMBL29837352 0.86 ADORA2A (0.72) ADORA2AADORA3ADORA2BADORA1ALDH1A1
SCHEMBL23291341 0.86 ADORA2A (0.72) ADORA2AADORA3ADORA2BADORA1ALDH1A1
SCHEMBL23581217 0.85 ADORA2A (0.68) ADORA2AADORA3ADORA2BADORA1ALDH1A1
SCHEMBL23581209 0.84 ADORA2A (0.67) ADORA2AADORA3ADORA2BADORA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111164084-B Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2023-05-23 CN disclosed